双酸和酸作为转录因子STAT4的选择性抑制剂
Nadiya Brovchenko1, Angela Berg1, Sabine Schubert1
1Institute of Organic Chemistry, Leipzig University, Johannisallee 29, 04103, Leipzig, Germany.
Angewandte Chemie (International ed. in English)
|March 11, 2025
概括
研究人员开发了针对STAT4的新型小分子抑制剂,这是自身免疫性疾病的关键因素. 这些抑制剂对开发新疗法来治疗诸如类风湿性关节炎和多发性硬化症等疾病充满希望.
科学领域:
- 免疫学 免疫学 免疫学
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 信号转换器和转录4激活器 (STAT4) 在各种自身免疫性疾病的发展中起着至关重要的作用.
- STAT4与炎症性肠病,多发性硬化症,类风湿性关节炎和糖尿病的发病有关.
- 准STAT4为自身免疫性疾病提供了潜在的治疗策略.
研究的目的:
- 确定和开发第一个小分子抑制剂的STAT4.
- 描述这些抑制剂对STAT4.4的强度和选择性.
- 在细胞模型中评估STAT4抑制的治疗潜力.
主要方法:
- 作为STAT4抑制剂的p-基酸盐和酸盐的设计和合成.
- 生物化学测试以确定抑制剂功效 (Ki) 和针对STAT4和STAT3.3的选择性.
- 热变性试验用于评估受抑制剂介导的蛋白质稳定.
- 基于细胞的测定以测量细胞透性前药物的STAT4酸化抑制.
主要成果:
- 酸和酸被确定为第一个小分子STAT4抑制剂.
- 最强效的抑制剂对STAT4 SH2域表现出亚微分子强度,比STAT3.3具有14倍的选择性.
- 开发的抑制剂Stafori-1稳定了STAT4的热变性,其前代药物Pomstafori-1选择性地抑制了人类细胞中的STAT4酸化.
- 抑制剂对STAT4表现出选择性,而不是与之密切相关的STAT3.
结论:
- 已经成功开发出了STAT4的小分子抑制剂.
- 这些抑制剂表现出强烈和选择性抑制STAT4.
- 这些发现支持STAT4作为治疗自身免疫性疾病的可用药物标,有未满足的医疗需求.
相关概念视频
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Eukaryotic Transcription Inhibitors
9.7K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.7K
Amplifying Signals via Enzymatic Cascade
8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Protein Kinases and Phosphatases
13.0K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.0K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


